We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Novel Microfluidic HIV Test Is Quick and Inexpensive

By LabMedica International staff writers
Posted on 03 Aug 2010
A simple blood test, using a microarray, can capture specific white blood cells and cytokines to monitor patients infected with Human Immunodeficiency Virus (HIV). More...


The test consists of polymer film imprinted with an array of miniature spots. Each spot contains antibodies specific to the two kinds of leukocytes surface antigens (CD4 and CD8) and three types of cytokines printed in the same array.

When the blood is applied to the film and flows across the antibody spots, T-cell leukocytes stick on the spots. Each T-cell type is captured next to antibody spots specific for the cytokines they might produce. When antibodies activate the cells, spots adjacent to the cells capture the cytokines they secrete. This connects a specific T-cell subset to its secreted cytokines. The visible color intensity of antibody spots revealed differences in cytokine production by T-cells.

The antibody microarray is integrated with a lens-free holographic imaging device that takes only seconds to count the number of captured cells and amount of secreted cytokine molecules. The test returns results six to twelve times faster than traditional approaches and tests six parameters simultaneously, based on a small blood sample.

The visible color intensity of antibody spots revealed differences in cytokine production by T-cells. The lens-free on-chip imaging allowed the scientists to rapidly image and count T-cell arrays without the use of any lenses or mechanical scanning. Analysis of CD4 and CD8 T-cell numbers, the CD4/CD8 ratio, and three secreted cytokines takes only seconds.

The device was developed at the University of California (UCDavis; Davis, CA, USA) by Professor Alexander Revzin, Ph.D., the principle biochemical engineer. He explains, "While the point of care field focuses on detection of single parameter (e.g., CD4 counts), we believe that the simplicity of the test need not compromise information content. So, we set out to develop a test that could be simple and inexpensive, but would provide several parameters based on a single injection of a small blood volume." The device will be useful for blood transfusion monitoring, where the safety of blood is frequently in question.

The study was published in the May 2010 issue of Analytical Chemistry.

The tandem use of antibody microarrays and lens free holographic imaging, paves the way for future development of miniature cytometry devices for multiparametric blood analysis at the point of care or in a resource-limited setting.

Related Links:
University of California at Davis



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Melanoma Panel
UltraSEEK Melanoma Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.